ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 152,42
-0,06%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. GeoVax Labs Inc (GOVXW)

  7. GeoVax Labs Inc (GOVXW) Actualités

GOVXW GeoVax Labs Inc

0,0364
0,00 (0,00%)
14 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
GeoVax Labs Inc GOVXW NASDAQ Warrant
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 0,0364 22:02:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,0364 0,0364
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
07/6/202422:01EDGAR2Form S-1 - General form for registration of securities under..
24/5/202422:04EDGAR2Form 8-K - Current report
23/5/202422:07EDGAR2Form 8-K - Current report
21/5/202423:23EDGAR2Form 8-K - Current report
21/5/202418:32EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
15/5/202422:03EDGAR2Form 8-K - Current report
14/5/202423:09EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/5/202423:09EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/5/202423:08EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/5/202423:07EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/5/202422:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
04/4/202418:30GLOBEGeoVax Presents Data on GEO-CM04S1, a Next Generation..
28/3/202414:00GLOBEGeoVax to Present Data on GEO-CM04S1, a Next Generation..
12/3/202414:00GLOBEGeoVax to Present at the 36th Annual Roth Conference
06/3/202415:00GLOBEGeoVax Achieves Milestone in Transition to Commercially..
29/2/202422:00GLOBEGeoVax Reports 2023 Year-End Financial Results and Provides..
22/2/202415:00GLOBEGeoVax to Report 2023 Financial Results and Provide..
19/2/202415:00GLOBEGeoVax to Present at the 2024 BIO CEO & Investor Conference
13/2/202415:00GLOBEGeoVax Announces Multiple Patent Issuances and Allowances
06/2/202415:00GLOBEGeoVax Reports Positive Interim Data From Phase 2 Clinical..
29/1/202415:00GLOBEGeoVax Announces 1-for-15 Reverse Stock Split to Regain..
08/1/202415:00GLOBEGeoVax Appoints Dr. Marc Pipas as Executive Medical..
04/1/202415:00GLOBEGeoVax Announces Gedeptin® Patient Enrollment Closure for..
03/1/202415:00GLOBEGeoVax Announces Issuance of Malaria Vaccine Patent
27/12/202315:00GLOBEGeoVax to Present at Biotech Showcase During J.P. Morgan..
19/12/202315:00GLOBEGeoVax Expands Rights Under NIH COVID-19 License to Include..
30/11/202322:30GLOBEGeoVax Hemorrhagic Fever Vaccine Data Presented at World..
29/11/202315:00GLOBEGeoVax to Participate in Upcoming December Investor Events
28/11/202315:00GLOBEGeoVax COVID-19 Vaccine Clinical Data Presented at World..
14/11/202315:00GLOBEProgress on GeoVax’s Universal Coronavirus Vaccine..
08/11/202322:00GLOBEGeoVax Reports Third Quarter 2023 Financial Results and..
31/10/202314:00GLOBEGeoVax to Report Third Quarter 2023 Financial Results and..
30/10/202314:00GLOBEGeoVax Commences Site Expansion for Phase 2 Trial of..
25/10/202315:00GLOBEGeoVax to Participate in Upcoming November Investor and..
24/10/202315:00GLOBEGeoVax Update: Clinical and Operational Progress Toward..
09/10/202315:00GLOBEGeoVax Receives Notice of Allowance for Marburg Vaccine..
05/10/202315:00GLOBEGeoVax Receives Notice of Allowance for HIV Vaccine Patent
27/9/202315:00GLOBEGeoVax to Participate in Upcoming October Investor and..
26/9/202315:00GLOBEGeoVax Secures Multi-Product License for ProBioGen's..
20/9/202315:00GLOBEGeoVax Next-Generation COVID-19 Vaccine Data Presented at..
19/9/202315:00GLOBEGeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent..
12/9/202315:00GLOBEGeoVax Presents Corporate Update at the H.C. Wainwright 25th..
11/9/202315:00GLOBEGeoVax Completes Enrollment of Phase 2 Trial for..
31/8/202315:00GLOBEGeoVax to Present at the H.C. Wainwright 25th Annual Global..
28/8/202315:00GLOBEGeoVax Receives Notice of Allowance for Malaria Vaccine..
10/8/202315:00GLOBEGeoVax Announces First Patients Vaccinated in Phase 2..
09/8/202322:00GLOBEGeoVax Reports 2023 Second Quarter Financial Results and..
26/7/202315:00GLOBEGeoVax to Report Second Quarter 2023 Financial Results and..
24/7/202315:00GLOBEGeoVax Announces Issuance of Ebola Vaccine Patent
20/7/202315:00GLOBEGeoVax Announces Initiation of Phase 2 Clinical Trial of..

Dernières Valeurs Consultées

NASDAQ
GOVXW
GeoVax Labs
COIN
EXCGBP
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés